Inhibitors of PD-1 and PD-L1 disrupt the PD-1 axis, reversing T cell suppression and enhancing endogenous antitumor immunity, allowing patients with a variety of malignancies to experience long-term antitumor responses [12]. This evidence concerns the gene PDCD1 and cancer.